Tokyo, Nov. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059289) titled 'the efficacy of antiviral hepatitis therapy on psychiatric symptoms in psychiatric disorders complicated by viral hepatitis' on Nov. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Osaka Psychiatric Medical Center
Condition:
Condition - depression, schizophrenia, bipolar disorder, dementia with HCV or HBV infection
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - to examine whether antiviral therapy for hepatitis in patients with psychiatric disorders who also have infection with HCV or HBV leads to improvement of psychiatric symptoms.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 15
years-old
=
Gender - Male and Female
Key inclusion criteria - Outpatients or inpatients diagnosed with depression, schizophrenia, bipolar disorder, or dementia, who have infection with HCV or HBV, who meet the indication for antiviral therapy, and who wish to receive it. Those who, after sufficient explanation and full understanding, give their written consent voluntarily.
Key exclusion criteria - Those for whom it is judged difficult to assess psychiatric symptoms before and after antiviral therapy. Those whom the principal investigator deems inappropriate as subjects.
Target Size - 100
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 05 Month 31 Day
Date of IRB - 2025 Year 05 Month 31 Day
Anticipated trial start date - 2025 Year 08 Month 14 Day
Last follow-up date - 2027 Year 07 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067816
Disclaimer: Curated by HT Syndication.
